The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis
NCT ID: NCT03105505
Last Updated: 2018-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
75 participants
INTERVENTIONAL
2017-04-28
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Tolerability of Blephademodex Wipes
NCT04780165
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
NCT00349466
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
NCT04784091
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
NCT05322148
To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension
NCT03975374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group A (study group) patients will apply facially Permethrin 5% every night for 3 months.
Group B patients will apply on the eyelids Fusidic acid 1% every night for 3 months.
Group C patients will apply on the eyelids Synthomycine 5% every night for 3 months
Follow up Evaluation will be made after one week, one month, two months, three months, 4 months and half a year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Permethrin 5%
Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
Permethrin 5%
Facial skin application once a night for 3 months.
Synthomycine 5%,
Contains chloramphenicol 5%.
Synthomycine 5%
Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
Fusidic Acid 1%
Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
Fusidic Acid 1% M/R Eye Drops
viscous eye drops application once a night for 3 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Permethrin 5%
Facial skin application once a night for 3 months.
Synthomycine 5%
Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
Fusidic Acid 1% M/R Eye Drops
viscous eye drops application once a night for 3 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Barzilai Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Igor Kaiserman
Prof Igor Kaiserman
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barzilai Medical Center
Ashkelon, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
003-16-BRZ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.